Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aldeyra Therapeutics reports positive milestones and financial stability in Q4 2022

Aldeyra Therapeutics showcased positive performance in key milestones, financial stability, and progress in clinical studies, positioning the company for future growth.
Despite challenges in managing expenses and meeting enrollment deadlines, Aldeyra's strengths in its pipeline and financial position offer opportunities for success.
The upcoming year holds promise for Aldeyra with novel therapies addressing unmet medical needs and significant milestones expected in key trials.
Overall, Aldeyra's focus on advancing treatments for ocular and systemic conditions underscores its commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

The small-cap pharma announced positive results from a phase 3 trial.

Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today

News for Aldeyra Therapeutics Stock (ALDX)